Debu Tripathy on Using Breast Cancer Tumor DNA to Make Treatment Decisions
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses the potential for using breast cancer tumor DNA to make treatment decisions.
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses the potential for using breast cancer tumor DNA to make treatment decisions.
Researchers and oncologists have not been able to look at breast cancer tumor DNA to help determine if a certain treatment will work better than another, as they do for other diseases, such as lung cancer. But for breast cancer, Tripathy says, progress is needed.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
